Analysis manuscript live figures:

Figure 1: Overview of the trials and patient groups

Figure 2: Comparison of the 4 Cross-trial Analysis Categories

• Fig.2A-E: Entire cohort, WNT, SHH, Group 3, Group 4
• Fig.2F-G: Compares the cumulative doses of chemotherapy drugs, Compares the clinical target volume (CTV)

Figure 3: Comparison of cross-trial treatment categories containing HDCSI to HDCSI_Carbo

Figure 4: Exploring molecular and clinical risk in the SHH cohort

• Fig.4A: Univariate and Multivariate analysis of prognostic features
• Fig.4B: Clinical-molecular risk category assignment
• Fig.4C: Kaplan Meier PFS plot
• Fig.4C_inset: Kaplan Meier PFS plot pop up
• Fig.4D: Oncoprint

Figure 5: Exploring molecular and clinical risk in the G3/G4 cohort

• Fig.5A-C: Univariate and Multivariate analysis of prognostic features, Clinical-molecular risk category assignment, Kaplan Meier PFS plot
• Fig.5C_inset1: Kaplan Meier PFS plot upper pop-out
• Fig.5C_inset2: Kaplan Meier PFS plot lower pop-out
• Fig.5D: Oncoprint

Figure 6: A Sankey diagram illustrating how to deploy the new risk-stratification algorithm

Supplementary figures:

• Fig.S1A: Oncoprint
• Fig.S1B-D: Umap
• Fig.S2A-C: Distribution of molecular groups
• Fig.S2C(Age group 3-7 years): Patients in the age group 3-7 years
• Fig.S3A-E: Evaluation of LDCSI PFS relative to SDCSI PFS for all age patients
• Fig.S4A-E: Evaluation of LDCSI PFS relative to SDCSI PFS for age group 3-7 years
• Fig.S5A-E Fig.S6A-E: PFS comparison of cross-trial treatment categories
• Fig.S7: Kaplan Meier graph showing no PFS difference between rCM-G3/G4 HR patients with or without carboplatin in HDCSI treatment
• Fig.S8: Comparison of PFS Kaplan-Meier curves from G3/G4 risk-stratification methods

Portal manuscript live figures:

Figure 1: Data dictionary variables overview

Figure 2: Overview of the portal visualizations

• Fig.2A: Summary Plots
• Fig.2B: Survival Analysis
• Fig.2C: Cox Regression Analyses
• Fig.2D: Lollipop Plot
• Fig.2E: Matrix Plot
• Fig.2F: Methylome t-SNE Plot
• Fig.2G/H: Sample View

Figure 3: Correlating MYC amplification and iso17 with patient outcomes.

• Fig.3A-B,D: Custom grouping and survival analyses for standard care patients with iso17 and MYC
• Fig.3C: Cox Regression Analyses with filtering and custom variables

Figure 4: KBTBD4 mutations visualized on the methylome t-SNE

• Fig.4A: Lollipop plot for KBTBD4 mutations
• Fig.4B: Methylome t-SNE plot with KBTBD4 mutations overlaying molecular subgroups (MNP 12.8)

Supplementary figures

• Fig.S1: Overlaying MYC amplifications with molecular subgroups on methylome t-SNE
• Fig.S2: Matrix with KBTBD4 driver mutations
• Fig.S3a: Sequence read view for PARPDA (I310_R312delinsTSYKL)
• Fig.S3b: Sequence read view for SJMB067030 (R312delinsPTSIHML)
• Fig.S3c: Sequence read view for SJMBWES087 (R313insPRR)
• Fig.S4: Methylation array data for sample PARPDA and genomic locus view over KBTBD4
• Fig.S5: Single sample view for three rescued cases of KBTBD4